EverHint – Explosive Volume Breakout – Top 3 Signals for Jun 23, 2026

3 signals. Healthcare leads (2). price range $40-$279. 2 with insider selling.

What This Signal Is

High momentum stock screener for swing trading opportunities. Identifies stocks with strong momentum characteristics suitable for swing trading (1-4 week holds). Includes multiple variants: breakout, pullback, aggressive momentum, and volatile high-beta.

Entry Criteria:

• Strong RSI momentum (configurable thresholds)
• Volume surge above average
• Price momentum confirmation
• Minimum ADV: $25M+ (varies by variant)
• Earnings buffer: 7 days pre/post earnings
• Variant-specific filters applied

Holding period: 1-4 weeks | Risk level: Medium-High

Market Context

Monday's session reflects a notable risk-off shift, with tech-heavy indices bearing the brunt of selling pressure as the Nasdaq drops over 2% while the Dow holds relatively steady — a classic divergence signaling rotation away from high-beta growth names. The VIX spike of over 12% to 19.39 confirms that options markets are pricing in elevated near-term uncertainty, which cuts both ways for momentum swing strategies: wider intraday ranges create larger potential moves, but also increase the likelihood of whipsaw entries and stop-outs if position sizing isn't carefully managed.

For momentum swing signals specifically, this environment demands heightened selectivity. Elevated volatility tends to amplify breakouts and breakdowns alike, meaning signals that align with the broader trend direction carry more conviction, while counter-trend setups carry meaningfully higher risk. The S&P 500's 1.43% decline suggests the path of least resistance remains to the downside in the short term, which would favor momentum signals on the short side or in defensive positioning.

Healthcare's emergence as the top sector for today's signals fits the current macro tone well. Defensive sectors like healthcare historically attract capital during risk-off rotations, as investors seek earnings stability and lower correlation to broader market volatility. With growth and technology under pressure, the sector rotation narrative supports healthcare-oriented momentum setups having stronger follow-through potential than signals in more cyclically exposed areas.

📊 Signals (3 of 3 total)

Ranked by composite momentum score (higher = stronger momentum)

Field Notes

Sector concentration: Healthcare (2), Industrials (1)

Insider selling: LGND (Ligand Pharmaceuticals Incorporated, -$2,745,061), CNTA (Centessa Pharmaceuticals plc, -$836,142)

Data coverage: 66.7% insider, 0.0% congressional, 0.0% earnings, 33.3% news

Peer Analysis

CNTA (Centessa Pharmaceuticals plc): Leads 5 peers: APGE ($132.88), XENE ($54.61), AAPG ($17.01), RARE ($28.76), CELC ($90.21)

LGND (Ligand Pharmaceuticals Incorporated): Leads 5 peers: PRAX ($305.37), BLTE ($145.09), MIRM ($111.07), ACAD ($22.60), ADMA ($8.69)

ACA (Arcosa, Inc.): Leads 5 peers: BZ ($13.14), NPO ($367.37), MSM ($116.26), ALK ($49.21), TREX ($45.34)

Recent Headlines

ACA (Arcosa, Inc.)

• Is CRH's $8.5 Billion Arcosa Acquisition a Game Changer?
• Arcosa Inc (ACA) Stock Up 6.7% but GF Value Says Overvalued -- GF Score: 78/100
• $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Arcosa, Inc. (NYSE: ACA)
• CRH to Acquire Arcosa for $8.5 Billion Amid Market Skepticism
• Shareholder Alert: Ademi LLP investigates whether Arcosa, Inc. is obtaining a Fair Price for Public Shareholders
• ACA Stock Alert: Halper Sadeh LLC is Investigating Whether Arcosa, Inc. is Obtaining a Fair Price for its Shareholders
• Stock Futures Cautiously Higher Amid Middle East Uncertainty
• Arcosa Stock Rises on $8.5 Billion Acquisition by CRH

Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.

👉 This is not financial advice. Market conditions change rapidly.
Do your own due diligence.

📢 Support the project by liking, sharing, or subscribing — it helps more readers discover these signals.